Literature DB >> 16205642

EphB4 receptor tyrosine kinase is expressed in bladder cancer and provides signals for cell survival.

G Xia1, S R Kumar, J P Stein, J Singh, V Krasnoperov, S Zhu, L Hassanieh, D L Smith, M Buscarini, D Broek, D I Quinn, F A Weaver, P S Gill.   

Abstract

We sought to evaluate the biological function of the receptor tyrosine kinase EphB4 in bladder cancer. All of the nine bladder cancer cell lines examined express EphB4 and the receptor could be phosphorylated following stimulation with its cognate ligand, EphrinB2. Out of the 15 fresh bladder cancer specimens examined, 14 expressed EphB4 with a mean sevenfold higher level of expression compared to adjacent normal urothelium. EphB4 expression was regulated by several mechanisms: EPHB4 gene locus was amplified in 27% tumor specimens and 33% cell lines studied; inhibition of EGFR signaling downregulated EphB4 levels; and forced expression of wild-type p53 reduced EphB4 expression. EphB4 knockdown using specific siRNA and antisense oligodeoxynucleotides molecules led to a profound inhibition in cell viability associated with apoptosis via activation of caspase-8 pathway and downregulation of antiapoptotic factor, bcl-xl. Furthermore, EphB4 knockdown significantly inhibited tumor cell migration and invasion. EphB4 knockdown in an in vivo murine tumor xenograft model led to a nearly 80% reduction in tumor volume associated with reduced tumor proliferation, increased apoptosis and reduced tumor microvasculature. EphB4 is thus a potential candidate as a predictor of disease outcome in bladder cancer and as target for novel therapy.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16205642     DOI: 10.1038/sj.onc.1209108

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  44 in total

1.  Expression of the EPHB4 receptor tyrosine kinase in head and neck and renal malignancies--implications for solid tumors and potential for therapeutic inhibition.

Authors:  Benjamin D Ferguson; Maria S Tretiakova; Mark W Lingen; Parkash S Gill; Ravi Salgia
Journal:  Growth Factors       Date:  2014-11-13       Impact factor: 2.511

Review 2.  Eph receptors and ephrins in cancer: bidirectional signalling and beyond.

Authors:  Elena B Pasquale
Journal:  Nat Rev Cancer       Date:  2010-03       Impact factor: 60.716

Review 3.  Molecular markers of prognosis and novel therapeutic strategies for urothelial cell carcinomas.

Authors:  Christopher Y Thomas; Dan Theodorescu
Journal:  World J Urol       Date:  2006-11       Impact factor: 4.226

Review 4.  Essential roles of EphB receptors and EphrinB ligands in endothelial cell function and angiogenesis.

Authors:  Ombretta Salvucci; Giovanna Tosato
Journal:  Adv Cancer Res       Date:  2012       Impact factor: 6.242

Review 5.  Eph/ephrin signaling in the kidney and lower urinary tract.

Authors:  Anna-Carina Weiss; Andreas Kispert
Journal:  Pediatr Nephrol       Date:  2015-04-23       Impact factor: 3.714

6.  KSR1 and EPHB4 Regulate Myc and PGC1β To Promote Survival of Human Colon Tumors.

Authors:  Jamie L McCall; Drew Gehring; Beth K Clymer; Kurt W Fisher; Binita Das; David L Kelly; Hyunseok Kim; Michael A White; Robert E Lewis
Journal:  Mol Cell Biol       Date:  2016-08-12       Impact factor: 4.272

7.  Expression of EphrinB2 and EphB4 in glioma tissues correlated to the progression of glioma and the prognosis of glioblastoma patients.

Authors:  Yanyang Tu; Shiming He; Jianfang Fu; Gang Li; Ruxiang Xu; Hongliu Lu; Jianping Deng
Journal:  Clin Transl Oncol       Date:  2012-03       Impact factor: 3.405

Review 8.  Personalized cancer medicine--advances and socio-economic challenges.

Authors:  David B Jackson; Anil K Sood
Journal:  Nat Rev Clin Oncol       Date:  2011-10-11       Impact factor: 66.675

9.  Down-regulation of EphB4 phosphorylation is necessary for esophageal squamous cell carcinoma tumorigenecity.

Authors:  Fengqing Hu; Zhen Tao; Zhenya Shen; Xiaolin Wang; Fei Hua
Journal:  Tumour Biol       Date:  2014-04-27

10.  Design, synthesis and characterization of novel small molecular inhibitors of ephrin-B2 binding to EphB4.

Authors:  Srinivas Duggineni; Sayantan Mitra; Roberta Noberini; Xiaofeng Han; Nan Lin; Yan Xu; Wang Tian; Jing An; Elena B Pasquale; Ziwei Huang
Journal:  Biochem Pharmacol       Date:  2012-12-17       Impact factor: 5.858

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.